Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Sales and Divestitures (2021 - 2025)

Syndax Pharmaceuticals (SNDX) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $410707.0 as the latest value for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 380.39% year-over-year to $410707.0; the TTM value through Dec 2025 reached $410707.0, up 380.39%, while the annual FY2025 figure was $410707.0, 380.39% up from the prior year.
  • Gains from Sales and Divestitures hit $410707.0 in Q4 2025 for Syndax Pharmaceuticals, up from $85495.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $410707.0 in Q4 2025 and bottomed at $3750.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $55932.5, with a median of $9102.0 recorded in 2023.
  • Year-over-year, Gains from Sales and Divestitures crashed 76.51% in 2023 and then skyrocketed 839.3% in 2024.
  • Syndax Pharmaceuticals' Gains from Sales and Divestitures stood at $5500.0 in 2021, then surged by 604.55% to $38750.0 in 2022, then plummeted by 76.51% to $9102.0 in 2023, then surged by 839.3% to $85495.0 in 2024, then soared by 380.39% to $410707.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $410707.0, $85495.0, and $9102.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.